On August 4, 2026, Tiziana Life Sciences Ltd announced that Chief Executive Officer Ivor Elrifi purchased 667,000 common shares on NASDAQ at $1.00 per share. This transaction increased his total holdings to 4,472,261 common shares. The company is a clinical-stage biopharmaceutical firm developing immunomodulation therapies, specifically its lead candidate intranasal foralumab.
